An engineered IL-21 variant is a potent antitumor candidate for antitumor immunotherapy
{{output}}
IL-21, as an immune agonist, has demonstrated limited therapeutic efficacy in cancer immunotherapy. To overcome this inherent limitation, we constructed a yeast surface-displayed IL-21 mutant library guided by the structure of the IL-21/IL-21 receptor (IL-21R)... ...
